Corticosteroid Therapy Guidelines

Introduction to Corticosteroid Use

The American College of Rheumatology recommends oral prednisone as the standard first-line corticosteroid for most inflammatory conditions requiring systemic glucocorticoid therapy 1, 2, 3
The European League Against Rheumatism suggests that methylprednisolone should be reserved for specific clinical scenarios, such as intramuscular depot formulations when adherence is impossible, high-dose pulse therapy for severe disease, or when lower cumulative glucocorticoid exposure is critical in high-risk patients 1, 2, 3

Oral prednisone is the standard first-line corticosteroid for most inflammatory conditions requiring systemic glucocorticoid therapy, with well-established dosing across multiple conditions and extensive clinical experience 1, 2, 3

Consider IM methylprednisolone 120 mg every 3 weeks when oral medication adherence is impossible or unreliable, particularly in patients with polymyalgia rheumatica who cannot comply with daily oral regimens 1, 2, 3
IM methylprednisolone should be considered in female patients with difficult-to-control comorbidities, such as hypertension, diabetes, osteoporosis, or glaucoma, where minimizing cumulative corticosteroid dose is essential 1, 2, 3
IV methylprednisolone 10-30 mg/kg/day (or 500-1000 mg/day) is preferred for pulse therapy in severe, life-threatening conditions, such as multisystem inflammatory syndrome in children (MIS-C) or severe SLE nephritis 4
The American Thoracic Society recommends IV methylprednisolone 125 mg every 6 hours for 72 hours followed by oral prednisone as an alternative to oral prednisone 40 mg/day for 10 days in hospitalized COPD exacerbations 5

When converting between agents, use the 5:1 potency ratio, where prednisone 5 mg is equivalent to methylprednisolone 4 mg, and hydrocortisone 400 mg IV per 24 hours is equivalent to methylprednisolone 60 mg IV per 24 hours 6

Doses ≥40-60 mg/day of prednisone (or equivalent methylprednisolone ≥32-48 mg/day) can induce clinically significant myopathy, with total cumulative doses exceeding 1 gram of methylprednisolone substantially increasing myopathy risk 7
The American College of Rheumatology recommends monitoring for myopathy with serial CPK when using high doses (≥40-60 mg/day prednisone equivalent) or cumulative doses >1 gram methylprednisolone 7

The panel acknowledges significant evidence gaps for IM methylprednisolone, with efficacy supported by only a single randomized controlled trial requiring confirmation, and failed to demonstrate reduction in glucocorticoid-related adverse events except weight gain 1, 2, 3